VRDN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
VRDN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-06-05), Viridian Therapeutics's current share price is $11.99. Viridian Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $92.56. Viridian Therapeutics's Cyclically Adjusted PS Ratio for today is 0.13.
The historical rank and industry rank for Viridian Therapeutics's Cyclically Adjusted PS Ratio or its related term are showing as below:
During the past years, Viridian Therapeutics's highest Cyclically Adjusted PS Ratio was 0.27. The lowest was 0.10. And the median was 0.18.
VRDN's Cyclically Adjusted PS Ratio is ranked better thanThe Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Viridian Therapeutics's adjusted revenue per share data for the three months ended in Mar. 2024 was $0.001. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $92.56 for the trailing ten years ended in Mar. 2024.
The historical data trend for Viridian Therapeutics's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viridian Therapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Cyclically Adjusted PS Ratio | Get a 7-Day Free Trial | 0.20 | 0.20 | 0.14 | 0.22 | 0.19 |
For the Biotechnology subindustry, Viridian Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Viridian Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Viridian Therapeutics's Cyclically Adjusted PS Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Viridian Therapeutics's Cyclically Adjusted PS Ratio for today is calculated as
Cyclically Adjusted PS Ratio | = | Share Price | / | Cyclically Adjusted Revenue per Share |
= | 11.99 | / | 92.56 | |
= | 0.13 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viridian Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:
For example, Viridian Therapeutics's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:
Adj_RevenuePerShare | = | Revenue per Share | / | CPI of Mar. 2024 (Change) | * | Current CPI (Mar. 2024) |
= | 0.001 | / | 131.7762 | * | 131.7762 | |
= | 0.001 |
Current CPI (Mar. 2024) = 131.7762.
Viridian Therapeutics Quarterly Data
Revenue per Share | CPI | Adj_RevenuePerShare | |
201406 | 424.667 | 100.560 | 556.496 |
201409 | 72.278 | 100.428 | 94.839 |
201412 | 38.529 | 99.070 | 51.249 |
201503 | 24.808 | 99.621 | 32.815 |
201506 | 20.971 | 100.684 | 27.447 |
201509 | 13.917 | 100.392 | 18.268 |
201512 | 14.021 | 99.792 | 18.515 |
201603 | 17.042 | 100.470 | 22.352 |
201606 | 18.208 | 101.688 | 23.595 |
201609 | 18.521 | 101.861 | 23.960 |
201612 | 15.429 | 101.863 | 19.960 |
201703 | 0.600 | 102.862 | 0.769 |
201706 | 0.503 | 103.349 | 0.641 |
201709 | 1.134 | 104.136 | 1.435 |
201712 | 0.801 | 104.011 | 1.015 |
201803 | 2.709 | 105.290 | 3.390 |
201806 | 1.080 | 106.317 | 1.339 |
201809 | 0.461 | 106.507 | 0.570 |
201812 | 0.231 | 105.998 | 0.287 |
201903 | 0.181 | 107.251 | 0.222 |
201906 | 1.217 | 108.070 | 1.484 |
201909 | 0.335 | 108.329 | 0.408 |
201912 | 0.408 | 108.420 | 0.496 |
202003 | 0.273 | 108.902 | 0.330 |
202006 | 0.047 | 108.767 | 0.057 |
202009 | 0.000 | 109.815 | 0.000 |
202012 | 0.014 | 109.897 | 0.017 |
202103 | 0.229 | 111.754 | 0.270 |
202106 | 0.134 | 114.631 | 0.154 |
202109 | 0.019 | 115.734 | 0.022 |
202112 | 0.009 | 117.630 | 0.010 |
202203 | 0.008 | 121.301 | 0.009 |
202206 | 0.009 | 125.017 | 0.009 |
202209 | 0.035 | 125.227 | 0.037 |
202212 | 0.003 | 125.222 | 0.003 |
202303 | 0.002 | 127.348 | 0.002 |
202306 | 0.002 | 128.729 | 0.002 |
202309 | 0.002 | 129.860 | 0.002 |
202312 | 0.001 | 129.419 | 0.001 |
202403 | 0.001 | 131.776 | 0.001 |
Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Thank you for viewing the detailed overview of Viridian Therapeutics's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Stephen F. Mahoney | director, officer: President and CEO | C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11 |
Thomas W. Beetham | officer: Chief Operating Officer | C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11 |
Sarah Gheuens | director | C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139 |
Seth Harmon | officer: See Remarks | C/O VIRIDIAN THERAPEUTICS, INC., 221 CRESCENT STREET, SUITE 401, WALTHAM MA 02453 |
Lara Meisner | officer: General Counsel and Secretary | C/O VIRIDIAN THERAPEUTICS, INC., 203 CRESCENT STREET, BLDG. 17, SUITE 102, WALTHAM MA 02453 |
Scott Dunseth Myers | director, officer: Chief Executive Officer | C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121 |
Jonathan Violin | officer: President and COO | 955 CHESTERBROOK BOULEVARD, SUITE 200, CHESTERBROOK PA 19087 |
Barrett Katz | officer: Chief Medical Officer | 6200 LOOKOUT ROAD, C/O MIRAGEN THERAPEUTICS, INC., BOULDER CO 80301 |
Fairmount Healthcare Fund Gp Llc | director, other: See Remarks | 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103 |
Carrie Melvin | officer: COO | C/O VIRIDIAN THERAPEUTICS, INC., 203 CRESCENT STREET, BLDG 17, SUITE 102B, WALTHAM MA 02453 |
Frazier Life Sciences Public Fund, L.p. | 10 percent owner | TWO UNION SQUARE, 601 UNION ST., SUITE 3200, SEATTLE WA 98101 |
L.p. Fhmlsp, | 10 percent owner | C/O FRAZIER HEALTHCARE PARTNERS, 601 UNION STREET, SUITE 3200, SEATTLE WA 98101 |
Fhmlsp, L.l.c. | 10 percent owner | C/O FRAZIER HEALTHCARE PARTNERS, 601 UNION STREET, SUITE 3200, SEATTLE WA 98101 |
Kristian Humer | officer: CFO and CBO | C/O VIRIDIAN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, BOULDER CO 80301 |
Jennifer K. Moses | director | 79 TW ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709 |
From GuruFocus
By Business Wire • 01-08-2024
By sperokesalga sperokesalga • 05-04-2023
By sperokesalga sperokesalga • 05-08-2023
By ACCESSWIRE • 07-17-2023
By Business Wire • 01-17-2024
By Stock market mentor Stock market mentor • 02-07-2023
By Business Wire • 07-06-2023
By Business Wire Business Wire • 06-13-2023
By Business Wire • 09-25-2023
By sperokesalga sperokesalga • 04-12-2023